The first human confirmation of the utility of WT1-specific TCR-transduced autologous T cells in the context of HLA-A*24:02 for treatment of refractory AML or high-risk MDS came in clinical trial UMIN000011519 (29). This evidence concerns the gene HLA-A and acute myeloid leukemia.